|
Cancer site
|
Simvastatin-allocated (10,269)
|
Placebo-allocated (10,267)
|
Event rate ratio (& 95% CI)
|
P-value
|
|---|
|
Respiratory
| | | | |
|---|
|
Lung/larynx
|
171 (1.7%)
|
157 (1.5%)
|
1.08 (0.87 – 1.34)
| |
|
Other
|
8 (0.1%)
|
10 (0.1%)
|
0.79 (0.32 – 2.00)
| |
|
Subtotal: Respiratory
|
179 (1.7%)
|
167 (1.6%)
|
1.06 (0.86 – 1.31)
|
0.6
|
|
Gastrointestinal
| | | | |
|
Upper GI
|
74 (0.7%)
|
62 (0.6%)
|
1.18 (0.84 – 1.65)
| |
|
Colon/rectum
|
114 (1.1%)
|
131 (1.3%)
|
0.86 (0.67 – 1.11)
| |
|
Other
|
41 (0.4%)
|
33 (0.3%)
|
1.23 (0.78 – 1.94)
| |
|
Subtotal: Gastrointestinal
|
228 (2.2%)
|
223 (2.2%)
|
1.01 (0.84 – 1.22)
|
0.9
|
|
Connective tissue
| | | | |
|
Female breast
|
38 (1.5%)
|
51 (2.0%)
|
0.74 (0.49 – 1.12)
| |
|
Melanoma
|
17 (0.2%)
|
10 (0.1%)
|
1.66 (0.78 – 3.54)
| |
|
Other
|
5 (0.0%)
|
7 (0.1%)
|
0.71 (0.23 – 2.20)
| |
|
Subtotal: Connective tissue
|
60 (0.6%)
|
68 (0.7%)
|
0.87 (0.62 – 1.24)
|
0.4
|
|
Genitourinary
| | | | |
|
Renal
|
23 (0.2%)
|
22 (0.2%)
|
1.04 (0.58 – 1.86)
| |
|
Bladder
|
74 (0.7%)
|
90 (0.9%)
|
0.81 (0.60 – 1.11)
| |
|
Prostate
|
145 (1.9%)
|
145 (1.9%)
|
0.99 (0.79 – 1.25)
| |
|
Gynaecological
|
19 (0.7%)
|
18 (0.7%)
|
1.05 (0.55 – 2.00)
| |
|
Other
|
6 (0.1%)
|
6 (0.1%)
|
0.99 (0.32 – 3.08)
| |
|
Subtotal: Genitourinary
|
259 (2.5%)
|
272 (2.6%)
|
0.94 (0.80 – 1.12)
|
0.5
|
|
Haematological
| | | | |
|
Leukaemia/lymphoma
|
42 (0.4%)
|
32 (0.3%)
|
1.30 (0.82 – 2.05)
| |
|
Other
|
23 (0.2%)
|
23 (0.2%)
|
0.99 (0.55 – 1.76)
| |
|
Subtotal: Haematological
|
64 (0.6%)
|
52 (0.5%)
|
1.22 (0.85 – 1.75)
|
0.3
|
|
Other & unspecified
|
54 (0.5%)
|
57 (0.6%)
|
0.94 (0.65 – 1.36)
|
0.7
|
|
ALL CANCERS*
|
814 (7.9%)
|
803 (7.8%)
|
1.00 (0.91 – 1.11)
|
0.9
|
- * Prespecified that analyses of cancer incidence were to exclude non-melanoma skin cancer (243 [2.4%] simvastatin-allocated versus 202 [2.0%] placebo-allocated; p = 0.06).
